Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model

Life Sciences

Volumn 73, Issue 26, 2003, Pages 3323-3337

  Hasirci, Vasif ^a   Bonney, Iwona ^b   Goudas, Leonidas C ^b   Shuster, Louis ^c   Carr, Daniel B ^b   Wise, Donald L ^d,e  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Northeastern University   (United States)

^e Cambridge Scientific Inc   (United States)

Author keywords

Bupivacaine; Chronic constriction injury; Controlled drug release; Hydromorphone; Pain management

Indexed keywords

BUPIVACAINE; HYDROMORPHONE; PLACEBO; POLYGLACTIN; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BIODEGRADABLE IMPLANT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEVICE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; FIBER; HEAT; HYPERALGESIA; HYPERESTHESIA; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; MALE; NERVE COMPRESSION; NERVE LIGATION; NONHUMAN; PROPHYLAXIS; RAT; SCIATIC NERVE; SIMULATION;

EID: 0142157531     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00615-5     Document Type: Article

References (34)

1. Abram S.E. Cancer Pain. 1989;Kluwer Academic Publishers, Dordrecht.
2. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat produces disorders of pain sensation like those seen in man. Pain. 33:1988;87-107.
3. Carr D.B., Cousins M.J. Spinal route of analgesia. Opioids and future options. Cousins M.J., Bridenbaugh P.O. Neural Blockade in Clinical Anesthesia and Management of Pain. 1998;915-983 Lippincott-Raven, Philadelphia, New York.
4. Carr D.B., Jacox A.K., Chapman C.R.et al. Acute Pain Management: Operative and Medical Procedures and Trauma. Clinical Practice Guideline No. 1. AHCPR Publication. vol. 92-0032:1992;U.S. Department of Health and Human Services, Rockville, MD.
5. Chary S., Goughnour B.R., Moulin D.E., Thorpe W.R., Harsanyi Z., Darke A.C. The dose response relationship of controlled-release codeine (codeine Contin) in chronic cancer pain. Journal of Pain Symptom Management. 9:1994;363-371.
6. Checketts M.R., Mackenzie N., Scott N.B., Bannister J. Comparison of S(-)-bupivacaine with racemic (RS)-bupivacaine in supraclavicular brachial plexus block. British Journal of Anaesthesia. 80:1998;594-598.
7. Cooper D.W., Turner G. Patient controlled extradural analgesia to compare bupivacaine, fentanyl and bupivacaine fentanyl in the treatment of postoperative pain. British Journal of Anaesthesia. 70:1993;503-507.
8. Curley J., Castillo J., Hotz J., Uezono M., Hernandez S., Lim J.-O., Tigner J., Chasin M. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology. 84:1996;1401-1410.
9. Dahm P.O., Nitescu P.V., Appelgren L.K., Curelaru I.D. Six years of continuous infusion of opioid and bupivacaine in the treatment of refractory pain due to intrapelvic extrusion of bone cement after total hip arthroplasty. Regional Anesthesia and Pain Medicine. 23:1998;315-319.
10. Dietz F.B., Jaffe R.A. Bupivacaine preferentially blocks ventral root axons in rats. Anesthesiology. 86:1997;172-180.
11. Ferrante F.M., Bedder M., Caplan R.A.et al. Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists task force on pain management, cancer pain section. Anesthesiology. 84:1996;1243-1257.
12. Grossman, S.A., Leong, K.W., Lesser, G.J., Lo, H., 1997. Subcutaneous Implant, US Patent 5,633,000.
13. Hamid S.K., Scott N.B., Sutcliffe N.P., Tighe S.Q., Anderson J.R., Cruikshank A.M., Kehlet H. Continuous coeliac plexus blockade plus intermittent wound infiltration with bupivacaine following upper abdominal surgery: a double-blind randomized study. Acta Anaesthesiologica Scandinavica. 36:1992;534-539.
14. Hargreaves K., Dubner R., Brown F., Flores C., Joris A. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88.
15. Hasirci V., Sendil D., Goudas L.C., Carr D.B., Wise D.L. Controlled release pain management systems. Wise D.L. Handbook of Pharmaceutical Controlled Release Technology. 2000;787-806 Marcel Dekker, New York.
16. Hays H., Hagen N., Thirlwell M., Dhaliwal H., Babul N., Harsanyi Z., Darke A.C. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic cancer pain. Cancer. 74:1994;1808-1815.
17. Jacox A., Carr D.B., Payne R.et al. Management of Cancer Pain. Clinical Practice Guideline. Agency for Health Care Policy and Research (AHCPR) Publication. vol. 94-0592:1994;U.S. Department of Health and Human Services, Rockville, MD.
18. Kopacz D.J., Thompson G.E. Celiac and hypogastric plexus, intercostal, interpleural, and peripheral neural blockade of the thorax and the abdomen. Cousins M.J., Bridenbaugh P.O. Neural Blockade in Clinical Anesthesia and Management of Pain. 1998;451-485 Lippincott Raven Publishers, Philadelphia, New York.
19. Lawlor P., Turner K., Hanson J., Bruera E. Dose ratio between morphine and HM in patients with cancer pain: a retrospective study. Pain. 72:1997;79-85.
20. Lesser G.J., Grossman S.A., Leong K.W., Lo H., Eller S. In vitro and in vivo studies of subcutaneous HM implants designed for the treatment of cancer pain. Pain. 65:1996;265-272.
21. Malinovsky J.M., Bernard J.M., Le Corre P., Dumand J.B., Lepage J.Y., Le Verge R., Souron R. Motor and blood pressure effects from epidural sustained release bupivacaine from polymer microspheres: A dose-response study in rabbits. Anesthesia & Analgesia. 81:1995;519-524.
22. Martinez V., Christensen D., Kayser V. The glycine/NMDA receptor antagonist (+)-HA966 enhances the peripheral effect of morphine in neuropathic rats. Pain. 99:2002;537-545.
23. Masters D.B., Berde C.B., Dutta S., Turek T., Langer R. Sustained local anesthetic release from bioerodible polymer matrices: a potential for prolonged regional analgesia. Pharmaceutical Research. 10:1993;1527-1532.
24. Merrill, S., Ayer, A.D., Chadha, N., Kuczynski, A.L., 1994. Hydromorphone Therapy, US Patent 5,529,787.
25. Merskey H., Bogduk N. Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. 1994;IASP Press, Seattle.
26. Payne R. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Seminars in Oncology. 25:1998;47-53.
27. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 1996;521-555 McGraw-Hill, New York. Chapter 23.
28. Rhodes D.J., Grossman S.A. Hydromorphone polymer implant. Journal of Substance Abuse and Treatment. 14:1997;535-542.
29. Singh H., Bossard R.F., White P.F., Yeatts R.W. Effects of ketorolac versus bupivacaine co-administration during patient-controlled hydromorphone epidural analgesia after thorocotomy procedures. Anesthesia & Analgesia. 84:1997;564-569.
30. Sjoberg M., Karlsson P., Nordborg C., Wallgren A., Nitescu P., Appelgren L., Linder L.E., Curelaru I. Neuropathological findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology. 76:1992;173-186.
31. Truong W., Cheng C., Xu Q.G., Li X.Q., Zochodne D.W. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Annals of Neurology. 53:2003;366-375.
32. Walker S.M., Goudas L.C., Cousins M.J., Carr D.B. Combination spinal analgesic chemotherapy: a systematic review. Anesthesia & Analgesia. 95:2002;674-715.
33. WHO Cancer Pain Relief with a Guide to Opioid Availability. 2nd ed. 1996;World Health Organization, Geneva.
34. Wilson P.R., Caplan R.A., Connis R.T.et al. Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists task force on pain management, chronic pain section. Anesthesiology. 86:1997;995-1004.